Keun Seok Lee
Poster presented at ASCO 2022 describing a HER2-targeted bispecific antibody in combination with chemotherapy, as first-line therapeutic options for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
Li Zhang
Exploring the combination of PD-1 inhibition and chemotherapy as an emerging therapeutic option for recurrent or metastatic nasopharyngeal carcinoma (RM NPC).

Chat with BeiGene

Close